

Bevacizumab

Essential medicine status

General description

Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits angiogenesis. It is used in the treatment of vascular eye diseases and in treatment protocols for some cancers.

INN

Bevacizumab

ATC codes

[S01LA08 L01FG01](#)

Medicine type

Biological agent

EML status history

First added in 2013 ([TRS 985](#)) for [Age related macular degeneration](#)

Application rejected in 2025 ([TRS 1064](#)) for [Hepatocellular carcinoma of liver](#)

Wikipedia

[Bevacizumab](#)

DrugBank

[Bevacizumab](#)

Recommendations

Section

Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations

- Parenteral > Locoregional injections > Intravitreal: 25 mg per mL

Indications

[Age related macular degeneration](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion; 25 mg per mL in 16 mL vial concentrate for solution for infusion

Indications

[Hepatocellular carcinoma of liver](#)